This post was originally published on this site
Veru, Inc. (NASDAQ:VERU) +20%; announced financial results for its fiscal 2022 third quarter ended June 30, 2022, and sabizabulin for COVID progress towards regulatory decisions in key territories.
Matterport, Inc. (MTTR) +20%; reported Q2 EPS of ($0.12), $0.02 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $28.5 million versus the consensus estimate of $29.6 million. Matterport, Inc. sees Q3 2022 EPS of ($0.15)-($0.13), versus the consensus of ($0.13). Matterport, Inc. sees Q3 2022 revenue of $35-37 million, versus the consensus of $32.95 million.
Walt Disney (NYSE:DIS) +10%; after the company reported stronger-than-expected Disney+ subscriber numbers for Q3.
Dutch Bros Inc. (BROS) +8%; reported Q2 EPS of $0.05, in-line with the analyst estimate of $0.05. Revenue for the quarter came in at $186.4 million versus the consensus estimate of $182.24 million.
InVitae (NVTA) -24%; surged 275% yesterday.
Sonos (NASDAQ:SONO) -17%; reported Q3 EPS of $0.19, $0.13 better than the analyst estimate of $0.06. Revenue for the quarter came in at $371.8 million versus the consensus estimate of $424.03 million. Sonos sees FY2022 revenue of $1.73-1.76 billion, versus the consensus of $1.96 billion.
Six Flags Entertainment (NYSE:SIX) -15%; reported Q2 EPS of $0.53, $0.51 worse than the analyst estimate of $1.04. Revenue for the quarter came in at $435 million versus the consensus estimate of $527.45 million.
Bumble (BMBL) -13%;reported Q2 EPS of ($0.03), $0.02 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $220 million versus the consensus estimate of $219.55 million.
AppLovin (APP) -10%; reported Q2 EPS of ($0.06), $0.21 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $776 million versus the consensus estimate of $839.67 million. AppLovin sees FY2022 revenue of $2.84-3.14 billion, versus the consensus of $3.29 billion.
GlaxoSmithKline (NYSE:GSK) -9% on worries related to Zantac litigation.
Sanofi (NASDAQ:SNY) -9% on worries related to Zantac litigation.
